Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Deferred Taxes (2021 - 2023)

Historic Deferred Taxes for Oncology Institute (TOI) over the last 3 years, with Q4 2023 value amounting to -$126000.0.

  • Oncology Institute's Deferred Taxes rose 7174.89% to -$126000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was -$126000.0, marking a year-over-year increase of 6818.18%. This contributed to the annual value of -$76000.0 for FY2023, which is 7110.27% up from last year.
  • As of Q4 2023, Oncology Institute's Deferred Taxes stood at -$126000.0, which was up 7174.89% from $80000.0 recorded in Q3 2023.
  • Over the past 5 years, Oncology Institute's Deferred Taxes peaked at $2.3 million during Q4 2021, and registered a low of -$3.8 million during Q3 2021.
  • Moreover, its 3-year median value for Deferred Taxes was -$4000.0 (2023), whereas its average is -$143727.3.
  • The largest annual percentage gain for Oncology Institute's Deferred Taxes in the last 5 years was 10138.33% (2022), contrasted with its biggest fall of 11942.51% (2022).
  • Oncology Institute's Deferred Taxes (Quarter) stood at $2.3 million in 2021, then plummeted by 119.43% to -$446000.0 in 2022, then skyrocketed by 71.75% to -$126000.0 in 2023.
  • Its Deferred Taxes stands at -$126000.0 for Q4 2023, versus $80000.0 for Q3 2023 and -$4000.0 for Q2 2023.